• Bone marrow adipocytes support AML survival.
Introduction
Survival of patients with acute myeloid leukemia (AML) is poor; two-thirds of young adults and 90% of older adults die of their disease. 1 Improved outcomes will now only come from novel treatment strategies derived from an improved understanding of the biology of the disease.
All mammals generate blood within their bones and AML arises from myeloid progenitors within the bone marrow (BM) microenvironment. AML blasts exhibit high levels of spontaneous apoptosis when cultured in vitro but have a prolonged survival time in vivo further indicating that the tissue microenvironment plays a critical role in promoting and maintaining AML cell survival. [2] [3] [4] [5] In human leukemias the microenvironment provides a number of soluble factors whose primary functions are to promote survival and homing, 6, 7 which implies that the apoptotic defect in AML is not cell-autonomous but highly dependent on extrinsic signals derived from the cellular microenvironment. These complex cell-cell interactions between AML blasts and the cells that support them within the bone marrow may therefore provide an attractive target for novel drug therapies.
The BM microenvironment is defined by cell types not directly involved in haematopoiesis and include: macrophages; endothelial cells; osteoclasts;
osteoblasts; adipocytes and fibroblasts. BM adipocytes were identified over a century ago, and bone marrow adipose tissue (MAT) accounts for up to 70% of BM volume of the axial skeleton in adult humans. [8] [9] [10] MAT is an energy storage organ and consists primarily of triglycerides which can be broken down to release free fatty acids (FA) which in turn can be used to generate ATP. In cancer, a recent study by Cawthorn et al (2014) , demonstrated that BM adiposity and circulating adiponectin increase in cancer therapy. 8 Moreover, TNF and adiponectin from the BM of patients with AML inhibit normal hematopoiesis. 11 However, although AML blasts are highly proliferative and grow within an adipocyte-rich environment, to date there is limited knowledge regarding the specific functions of BM adipocytes in relation to the proliferation and survival of AML.
Adipocytes, in the context of solid malignancies, support tumor survival, proliferation and metastasis. [12] [13] [14] In a study on breast cancer and the associated adipocytes
For personal use only. on January 6, 2017. by guest www.bloodjournal.org From therein, Dirat et al. (2011) showed that these cancer associated adipocytes are greatly influenced by the invasive cancer cells with which they are associated. 12 This study supports the concept of cancer cells orchestrating an environment which favours their progression through complex mechanisms by obtaining adipocyte participation. Furthermore, studies carried out in prostate cancer have demonstrated lipid transport between adipocytes and prostate cancer cells. 13, 15 In models of bone metastasis following prostate cancer, Herroon et al. (2013) , show functional evidence of BM adipocyte support of tumor growth and identify fatty acid binding protein-4 (FABP4) as a key protein involved in the mechanism. While this study investigates FABP4 expression in the cancer cells, a separate study has investigated FABP4 expression in ovarian cancer associated adipocytes. 14 FABP4 upregulation has been shown in the fat-rich omental metastases compared to the primary tumor site and mice lacking FABP4 show significant reduction in metastatic tumor growth, indicating the role of FABP4 in cancer proliferation and metastasis. Taken together, these studies identify a functional role for adipocytes and fatty acid transporters in the support of solid tumor metabolism and subsequent metastatic spread.
In the present study, we look to identify whether adipocytes directly support the proliferation of human AML. Furthermore we evaluate the mechanisms controlling the interaction between AML blasts and MAT, as well as the downstream metabolic consequences in both the adipocytes and leukemia cells. Finally, we identify key regulators in the AML/MAT interaction and assess AML survival following targeted inhibition of this interaction.
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Materials and Methods

Materials
Primary cell culture and differentiation
Primary AML blasts and non-malignant CD34+ cells were obtained from patient bone marrow or blood following informed consent and under approval from the UK National Research Ethics Service (LRECref07/H0310/146). Cell isolation was carried out by density gradient centrifugation using Histopaque (Sigma-Aldrich, Cat. 1077) and cell type was confirmed by flow cytometry. All cells were grown in normal media (Dulbecco's Modified Eagle's Medium (DMEM) (ThermoFisher, Cat. 21885-025) supplemented with 20% foetal bovine serum (FBS) (ThermoFisher, Cat.10082139)) with or without the addition of cytokines purchased from Peprotech, UK, 100 ng/ml SCF (300-07), 50 ng/ml FLT3L (300-19), 20 ng/ml IL-3 (200-03) and 20 ng/ml G-CSF (300-23). Bone marrow stromal cells (BMSC) were isolated from AML bone marrow samples by adherence to tissue culture plastic and were then expanded in DMEM containing 20% FBS and supplemented with 1% penicillin-streptomycin (ThermoFisher, Cat 15140122). BMSC markers were confirmed using flow cytometry for expression of CD90+, CD73+, CD105+ and CD45-. 16 To induce adipocyte differentiation of BMSC (passage 2-4), a cocktail of dexamethasone (1μM), indomethacin (0.2mM), insulin (100nM) and 3-isobutyl-1-methylxanthine (0.5mM) (Cat. D4902, 17378, I9278 and I7018) in DMEM containing 10% FBS was prepared.
The differentiation of BMSC to adipocytes was between 75%-95% as measured by Figure 3A and Supplementary figure 1B shows that differentiated adipocytes express higher levels of adiponectin, FABP4 and CEBPa than BMSC.
Flow cytometry
For this study we used the Accuri C6 (Bectin Deckinson, Oxford, UK) and the CyFlow Cube 6 (Sysmex, Milton Keynes, UK) for flow cytometry analysis. Cells were incubated for 5 minutes with the FCR receptor blocker (Miltenyi Biotec, Cat. 130-059-901) and then stained with isotype controls or test antibodies (Miltenyi Biotec).
Gates were set to the appropriate isotype control.
Co-culture assay
BMSC were seeded at 3 x10 4 
Proliferation, cell cycle and death assays
Treated primary AML blasts were incubated with 5-bromo-2'-deoxyuridine (BrdU staining kit, eBioscience, Cat. 8811-6600) and CD34 antibody. The proliferation percentage of cycling AML blasts were analysed using flow cytometry. Cell cycle analysis of AMLs from monoculture and co-culture was carried out by ethanol fixation and propidium iodide staining and quantified using flow cytometry. AML apoptosis was measured using PI/AnnexinV (eBiosciences, Cat. 88-8005-72) and was also quantified using flow cytometry.
Free fatty acid and glycerol detection
Free fatty acid and glycerol detection was performed using a lipolysis assay kit for detection of both free glycerol and fatty acids (Zenbio, Research Triangle, NC, Cat.
LIP-2-NC). AMLs were cultured with adipocytes in LIP2/3 assay buffer and incubated for 24 hours at 37C. Media was assayed to detect free fatty acid and glycerol according to manufacturer's specifications. 
Free fatty acid uptake assay
Western immunoblotting
Western analyses following SDS-PAGE were carried out as described. Whole cell lysates were extracted from AML/adipocyte co-culture and monocultures by using radioimmunoprecipitation assay buffer (RIPA) containing 1% NP-40 (Sigma-Aldrich, Gillingham, UK), 50 mmol/L Tris, 10% glycerol, 0.02% NaN3, 150 mmol/L NaCl, and a cocktail of phosphatase and protease inhibitors (Sigma-Aldrich, Gillingham, UK).
SDS-Page was performed as previously described.
17,19
Bioinformatic analysis
Publicly available RNA sequencing data were downloaded for a panel of 43 Clonogeneic methylcellulose assay 1 1 Primary AML blasts from adipocyte co-culture and monoculture were plated in methylcellulose medium (R&D Systems) at a density of 1 x 10 4 in all experiments.
Colonies were visualised and counted after 14 days. 
Statistical analysis
We used the Mann-Whitney U test to compare results between groups unless otherwise stated in the legends. Results with P < 0.05 were considered statistically significant (denoted by *). Results represent the mean ± Standard Deviation of 4 or more independent experiments. For Western blotting, data are representative images of 3 independent experiments. We generated statistics with Graphpad Prism
Results
BM Adipocytes support the survival and proliferation of primary AML.
Cellular proliferation is a highly energy-intensive process. Since adipocytes store energy in the form of triglycerides, we hypothesised that adipocytes provide energy in the form of fatty acids (FA) to AML blasts to support rapid growth. Initially, to determine the presence of lipids in AML we examined freshly isolated AML cells for lipid stores using the neutral lipid dye (BODIPY® 493/503) and find that freshly isolated AML cells (CD34+) contain abundant lipids ( figure 1A) . Figure 1B and 1C
shows that lipid stores using the neutral lipid dye are depleted in AML and nonmalignant CD34+ cells when cultured in vitro. Supplementary Figure 2 show that AML lose lipid content even when co-cultured with BMSC. As primary AML cells undergo spontaneous apoptosis when cultured in vitro to determine if adipocytes can support the survival of primary AML we cultured primary AML blasts, either alone or in co-culture with adipocytes derived from BM mesenchymal progenitor cells. Figure   1D and Supplementary Figure 3A show that primary AML blasts co-cultured with adipocytes (n=11) are protected from undergoing apoptosis for up to 6 days when compared to AML blasts cultured alone.
Next we wanted to determine if BM adipocytes can support the proliferation of primary AML blasts. Primary AML blasts increase in number when co-cultured with BM adipocytes for 6 days, compared to AML monoculture and AML cultured on BMSC (n=12) ( figure 1E ). Figure 1F shows that adipocytes also support nonmalignant CD34+ cell survival. Supplementary Figure 3B and 3C show that adipocytes support AML proliferation as measured by BrdU incorporation.
Supplementary figure 4 shows AML blasts on BMSC and adipocytes from the same patient. In AML blast colony forming cell (CFC) assays, adipocyte co-culture promoted CFC growth when compared to AML mono-culture ( Figure 1G ). Finally we showed that primary AML blasts from patient samples (n=4) which had been cultured on BM derived adipocytes for 6 days reliably engrafted NSG mice ( Figure 1H ). The same AML cells cultured in isolation did not engraft NSG mice after 12 weeks. AML were stained for CD33 and CD45 to confirm cell identity. 16, 22 We also examined the effect of cytokines on AML survival compared to co-culture with adipocytes.
Supplementary Figure 5A shows that there is a significant increase in survival of AML when cultured on adipocytes compared to with a media supplemented with
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AML blasts induce adipocyte lipolysis.
Our results indicate that adipocytes confer a proliferative advantage to primary AML.
We hypothesized that this could be due to transfer of FA from the adipocytes to AML. Therefore, to understand the effect AML cells have on adipocytes we assessed FA and glycerol release. Co-culture of AML with adipocytes increases FA and glycerol release compared to adipocyte and AML alone. (Figure 2A) . Moreover, nonmalignant CD34+ cells could also induce lipolysis of adipocytes, albeit at a much reduced quantity compared to AML (Figure 2A ). Supplementary figure 6A shows that conditioned media from AML can also induce adipocyte lipolysis. Moreover, Figure   2B shows that when we culture AML blasts with the FA, oleate, this supports the survival of AML. Lipolytic activation of adipocytes results from the phosphorylation of hormone sensitive lipase (HSL). Figure 2C shows that AML induced phosphorylated HSL (pHSL) in adipocytes. Conversely, acipomox (which is known to inhibit lipolysis, by inactivation of AMP activated protein kinase and downstream pHSL) inhibited AML proliferation when cultured on adipocytes but not alone or on BMSC ( Figure   2D ). Supplementary Figure 7 shows that adipocytes have significantly more HSL mRNA expression compared to BMSC and AML. To determine if lipids detected in the tumor cells after co-culture were derived from adipocytes, we cultured primary AML blasts with either adipocytes or BMSC that had previously been loaded with a fluorescent lipid dye (DAA). Supplementary Figure 8 shows loading of DAA into both BMSC and adipocytes. During co-culture we observed that lipids were transferred from adipocytes to AML (Fig. 2E, 2F and Supplementary Figure 9 ), moreover this transfer was inhibited by acipomox, thus supporting a model in which adipocytes provide lipids to support tumor growth.
FABP4 is important for the transfer of lipids from adipocytes to AML
FABP4 is a carrier protein for FA expressed in adipocytes, 23 and supports the movement of long chain fatty acids generated by lipolysis to the extracellular membrane and beyond. 24, 25 Additionally, increased FABP4 has been shown to be 1 4 involved in the transfer of FA from adipocytes to breast and ovarian cancer cells. 12, 14 We therefore examined the expression of FABP4 in human adipocytes and BMSC cultured with AML blasts or non-malignant CD34+ cells. RNA expression data shows that FABP4 levels are increased in adipocytes but not BMSC when cultured with AML, moreover non-malignant CD34+ cells had no effect on adipocyte FABP4
mRNA expression ( Figure 3A) . We also found that AML conditioned media could induced FABP4 up regulation in adipocytes (Supplementary Figure 10A) . Next we examined if other genes associated with lipolysis were also induced in adipocytes when cultured with AML. Supplementary Figure 11A shows that ATLG and MGLL mRNA expression are not changed in adipocytes when cultured with AML. In an apparent paradox, when the expression of FABP4 protein was examined, a reduction was observed in adipocytes cultured with AML compared to adipocytes alone ( Figure 3B ). FABP4 is known to be released from adipocytes as they transport the FA, 26 therefore FABP4 expression in the culture media was measured by a FABP4 specific ELISA. Figure 3C shows that culturing AML with adipocytes induces a release of FABP4 into the culture media. To determine if the FABP4 released by the adipocyte is taken up by the AML we used a recombinant FABP4 tagged to a His sequence. AML were cultured with and without the recombinant FABP4 for 4 hours. Figure 3D shows that no recombinant FABP4 was detected in AML. Next we examined if we could prevent the increase of lipids in AML blast by knockdown of FABP4 in the adipocyte. Figure 3E shows the knockdown FABP4 protein in adipocytes and figure 3F demonstrates that knockdown of adipocyte FABP4
inhibited the transfer of lipids to AML. Furthermore, FABP4 chemical inhibitor (BMS309403) inhibits AML blast survival but had no effect on non-malignant CD34+ cells ( Figure 3G ). Finally, FABP4 lentiviral knockdown in adipocytes ( Figure 3H) inhibits AML blast survival. Together these results demonstrate that FABP4 is critical for the transfer of FA from adipocytes to AML blasts.
As Herroon and colleagues have shown that FABP4 in prostate cancer cells is upregulated in response to culture with adipocytes, 15 we next examined whether FABP4 expression levels were elevated in AML cells extracted from bone marrow as compared to AML cells extracted from peripheral blood or non-malignant CD34+ cells. We found FABP4 expression to be significantly higher in AML bone marrow samples than in AML from peripheral blood or non-malignant CD34+ cells (P < 1 5 0.001, Wilcoxon rank-sum test) ( Figure 4A ). To confirm that this upregulation of FABP4 was a result of AML interacting with adipocytes rather than BMSC we examined FABP4 expression in AML cultured alone, with adipocytes or BMSC.
Supplementary figure 12 shows the purity of AML after separation from adipocytes co-culture. Figure 4B shows that FABP4 RNA is upregulated in AML in response to co-culture with adipocytes but not BMSC. We determined whether knockdown of FABP4 in AML cells could reduce survival when cultured on adipocytes. Figure 4C shows that FABP4-KD AML cells have reduced viability when co-cultured with adipocytes compared to co-culture with BMSC. Furthermore knockdown of AML FABP4 inhibited the transfer of lipids from adipocytes to AML ( figure 4D ).
Next, we sought to determine the functional role of FABP4 in an AML mouse model.
To do this we used a retroviral AML transplantation model where Hoxa9 and Meis1 are used to transform myeloid progenitor cells as described by Kroon et al (1998) . 27 Initially we determined if Hoxa9/Meis1-expressing cells could proliferate on adipocytes compared to BMSC or monoculture or monoculture without cytokine supplements. Figure 4E shows that Hoxa9/Meis1-expressing cells proliferate on adipocytes and BMSC. Next we knocked down FABP4 in Hoxa9/Meis1-expressing cells ( figure 4F ) and found that FABP4 KD reduced AML survival when cultured with adipocytes compared to media supplemented with cytokines or BMSC ( Figure 4G ).
Moreover, knockdown of FABP4 in Hoxa9/Meis1-expressing cells also reduces FA uptake, quantified by DAA fluorescence, when tumor cells were cultured on adipocytes ( Figure 4H ). Finally we show in vivo that FABP4-KD in Hoxa9/Meis1 expressing blasts significantly increases animal survival ( Figure 4I ). Taken together these results demonstrate that FABP4 in AML is essential for FA transport and tumor proliferation in the BM microenvironment.
Co-culture of AML with adipocytes activates β -oxidation in AML blasts
In order to study the reliance of AML blasts on adipocytes for their energy we first measured the cellular oxygen consumption rate (OCR) in AML blasts to determine levels of fatty acid oxidation (FAO). To confirm that AML blasts can use oxidation of exogenous fatty acid we assessed FAO by monitoring OCR upon addition of palmitate (FAO substrate) followed by addition of etomoxir (FAO inhibitor -ETX). Figure 5A shows that primary AML have increased OCR in the presence of palmitate
For personal use only. on January 6, 2017. by guest www.bloodjournal.org From which is inhibited by ETX this is compared to non-malignant CD34+ cells. Oxidation of exogenous fatty acid can be measured by examining OCR of AML blasts and nonmalignant CD34+ cells in response to ETX. Figure 5B and Supplementary Figure 13 shows that AML blasts cultured with adipocytes have increased FAO compared to AML blasts cultured alone or with BMSC and non-malignant CD34+ cells. In addition, we observed that AML blasts cultured on adipocytes had greater basal OCR compared to AML cultured alone or on BMSC ( Figure 5C ). OCR was reduced in AML co-cultured on adipocytes compared to BMSC with FABP4 knocked down compared to control KD cells ( Figure 5D ). Moreover, because of the nature of the OCR experiment in which AML were serum starved for 4 h prior to being loaded onto the Seahorse Bioanalyser we show that AML FABP4 mRNA levels were stable compared to non serum starved AML cells (Supplementary Figure 10B) . In addition, the FAO inhibitor ETX reduced AML blast survival when grown on adipocytes but not on BMSC (figure 5E).
ETX is a selective inhibitor of carnitine palmitoyltransferase-1 (CPT1A), which transports fatty acyl chains from the cytosol into the mitochondria, a process essential for the production of ATP from fatty acid oxidation. 28 We therefore examined the expression of various genes including CPT1A in AML when cultured with adipocytes. Supplementary Figure 11B shows that CPT1A, CPT2 and ACADL are all up-regulated in AML when cultured with adipocytes. Accordingly, we knockeddown CPT1A in AML blasts. Figure 5F shows a reduction in CPT1A mRNA and protein in human AML cells after infection with CPT1A shRNA lentivirus. Following successful knockdown of CPT1A in AML cells we found that CPT1A-KD AML cells have reduced viability when cultured with adipocytes compared to cells cultured on BMSC ( Figure 5G ). Finally, we tested the effect of CPT1A-KD in an AML patient derived xenograft model. Figure 5H shows that NSG mice engrafted with CPT1A-KD AML blasts from 2 patient samples have increased survival compared to control-KD NSG mice (n=4). Supplementary Figure 14 shows the bone marrow and spleen engraftment data for Figure 5H . We report that leukemia cells cause functional changes in non-malignant adipocytes, which ultimately leads to the transfer of free fatty acids from adipocytes to the AML blast. This is a FABP4 dependent process. FABP4 has intracellular functions in adipocytes but is also known to be actively secreted by adipocytes where it can exert specific biological functions in tissues other than it's origin. 31 Co-culture of AML and adipocytes results in transcriptional up-regulation of FABP4, in both in the adipocyte and the leukemic blast. Curiously however, we found that despite this transcriptional increase of FABP4 in the adipocytes, the intra-adipocyte protein level of FABP4 is decreased upon co-culture with AML. This led us to hypothesise that either (1) adipocyte FABP4 rapidly chaperones the FA from the adipocyte into the microenvironment (2) adipocyte FABP4 rapidly chaperones the FA from the 1 8 adipocyte into the AML cells or (3) excess intracellular FABP4 is simply degraded within the adipocyte. To consider this further we investigated the levels of FABP4 in the media of AML adipocyte co-cultures and confirmed FABP4 was released into the medium. In models of prostate cancer recombinant FABP4 is taken up by the malignant cells. 32 In our studies we also conducted experiments using recombinant FABP4 to determine if AML blasts actively take up this protein. We showed that no recombinant FABP4 was detected in AML after 4 hours of culture. These data suggest that unlike prostate cancer FA/FABP4 is not directly transferred from adipocyte to the AML cell but may be involved in an extracellular-to-membrane transport whereby it is degraded after functionality outside of the cell. Further studies would need to be conducted to confirm this hypothesis.
Maintenance of AML appears to depend on both the adipocyte and the leukemic comparatively modest. However, in contrast when FABP4 was knocked down in HoxA9/Meis1 cells, which were then injected into mice, we observed a more demonstrable anti-tumor effect. In addition we also found that our AML blasts maintained on adipocytes appeared to engraft (range 4-6 weeks) earlier than expected when compared to other reports in which primary AML blasts had not been previously cultured on adipocytes. [34] [35] [36] We have not investigated this observation formally but postulate that adipocytes may support the maintenance of primary leukemic progenitor cells. Overall, we suggest that our in-vivo model more closely recapitulates the complexity of a tumor growing within a patient than the in-vitro assays and also propose that adipocytes may improve efficiency of ex-vivo culture systems for primary human AML.
Blocking lipolysis using Acipomox or inhibiting transfer of free fatty acids using a 
CPT1A inhibitor, etomoxir, indicating that this FA oxidation signature is particularly associated with leukemic progenitors.
In summary, although adipocytes in the non-malignant setting appear to be negative regulators of hematopoietic microenvironment. 43 in the context of disease, adipocytes like other cells, can undergo distinct pathologic changes. 44 Here we report that in the setting of AML, BM derived adipocytes support tumor proliferation and survival. Specifically, AML blasts modulate intra-cellular adipocyte metabolism into a lipolytic state resulting in the release of FA into the microenvironment.
Ultimately, this free fatty acid is metabolically beneficial to the leukemia. Accordingly, 
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